Findeisen Peter, Kloor Matthias, Merx Sabine, Sutter Christian, Woerner Stefan M, Dostmann Nicole, Benner Axel, Dondog Bolormaa, Pawlita Michael, Dippold Wolfgang, Wagner Rudolf, Gebert Johannes, von Knebel Doeberitz Magnus
Department of Pathology, Institute of Molecular Pathology, University of Heidelberg, Germany.
Cancer Res. 2005 Sep 15;65(18):8072-8. doi: 10.1158/0008-5472.CAN-04-4146.
DNA mismatch repair deficiency is observed in about 10% to 15% of all colorectal carcinomas and in up to 90% of hereditary nonpolyposis colorectal cancer (HNPCC) patients. Tumors with mismatch repair defects acquire mutations in short repetitive DNA sequences, a phenomenon termed high-level microsatellite instability (MSI-H). The diagnosis of MSI-H in colon cancer is of increasing relevance, because MSI-H is an independent prognostic factor in colorectal cancer, seems to influence the efficacy of adjuvant chemotherapy, and is the most important molecular screening tool to identify HNPCC patients. To make MSI typing feasible for the routine pathology laboratory, highly reproducible and cost effective laboratory tests are required. Here, we describe a novel T25 mononucleotide marker in the 3'untranslated region of the CASP2 gene (CAT25) that displayed a quasimonomorphic repeat pattern in normal tissue of 200 unrelated individuals of Caucasian origin. In addition, CAT25 was monomorphic also in all tested donors of African and Asian origin (n = 102 and n = 79, respectively) and thus differs from the most commonly used markers BAT25 and BAT26. Without the analysis of corresponding normal tissue, CAT25 correctly detected 56 of 57 colorectal cancer specimens classified as MSI-H by using the standard National Cancer Institute/International Collaborative Group-HNPCC marker panel. Combined with the standard markers BAT25 and BAT26 in a multiplex PCR, all MSI-H colorectal cancer samples were typed correctly. No false-positive results were obtained in 60 non-MSI-H control colorectal cancer specimens. These data suggest that CAT25 should be included into novel marker panels for microsatellite testing thus allowing for a significant reduction of the complexity and costs of MSI typing. Moreover, CAT25 represents a highly promising marker for early detection of colorectal cancer in HNPCC germ line mutation carriers.
在所有结直肠癌中,约10%至15%存在DNA错配修复缺陷,在高达90%的遗传性非息肉病性结直肠癌(HNPCC)患者中也有发现。具有错配修复缺陷的肿瘤在短重复DNA序列中获得突变,这种现象称为高度微卫星不稳定(MSI-H)。结肠癌中MSI-H的诊断越来越重要,因为MSI-H是结直肠癌的独立预后因素,似乎会影响辅助化疗的疗效,并且是识别HNPCC患者的最重要分子筛查工具。为使MSI分型在常规病理实验室可行,需要高度可重复且具有成本效益的实验室检测。在此,我们描述了一种位于CASP2基因3'非翻译区的新型T25单核苷酸标记(CAT25),在200名白种人来源的无关个体的正常组织中显示出准单态重复模式。此外,CAT25在所有测试的非洲和亚洲血统供体(分别为n = 102和n = 79)中也是单态的,因此不同于最常用的标记BAT25和BAT26。在不分析相应正常组织的情况下,通过使用标准的美国国立癌症研究所/国际协作组-HNPCC标记面板,CAT25正确检测出57个被分类为MSI-H的结直肠癌标本中的56个。在多重PCR中与标准标记BAT25和BAT26结合使用时,所有MSI-H结直肠癌样本均被正确分型。在60个非MSI-H对照结直肠癌标本中未获得假阳性结果。这些数据表明,CAT25应纳入用于微卫星检测的新型标记面板,从而可显著降低MSI分型的复杂性和成本。此外,CAT25是HNPCC种系突变携带者早期检测结直肠癌的极有前景的标记。